This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
EJNMMI Radiopharmacy and Chemistry Open Access 09 January 2024
-
The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans
EJNMMI Research Open Access 21 May 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Ablynx's nanobody fragments go places antibodies cannot. Nat Biotechnol 35, 1115–1117 (2017). https://doi.org/10.1038/nbt1217-1115
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1217-1115
This article is cited by
-
Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
EJNMMI Radiopharmacy and Chemistry (2024)
-
Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics
Molecular Diversity (2023)
-
Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans
EJNMMI Research (2019)